Bio-Rad Laboratories Class A
500 hedge funds and large institutions have $9.46B invested in Bio-Rad Laboratories Class A in 2022 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 159 increasing their positions, 201 reducing their positions, and 70 closing their positions.
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
0.38% less ownership
Funds ownership: 77.19% → 76.81% (-0.38%)
7% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 70
3% less funds holding
Funds holding: 514 → 500 (-14)
12% less capital invested
Capital invested by funds: $10.8B → $9.46B (-$1.34B)
21% less repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 201
64% less call options, than puts
Call options by funds: $41.4M | Put options by funds: $115M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Veritas Asset Management
London,
United Kingdom
|
+$399M |
| 2 |
A
AustralianSuper
Melbourne,
Australia
|
+$202M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$74.4M |
| 4 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$50.4M |
| 5 |
Millennium Management
New York
|
+$46.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$126M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$118M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$115M |
| 4 |
BlackRock
New York
|
-$88.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$43.7M |
BIO Hedge Fund Activity: Q2 2022 in Review
500 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2022, worth a combined $9.46B — down 12% from $10.8B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of BIO and 65 opened new positions — a net loss of 5 holders — while 201 trimmed existing stakes and 159 added.
The largest buyer was Veritas Asset Management, opening a new position worth an estimated $399M. The largest seller was Marshall Wace, cutting an estimated $126M.
- 500 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2022, down from 514 in Q1 2022.
- Funds reported $9.46B of Bio-Rad Laboratories Class A stock for Q2 2022, down 12% quarter-over-quarter.
- 65 funds opened new Bio-Rad Laboratories Class A positions in Q2 2022 and 70 closed out, a net change of -5 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q2 2022 was Veritas Asset Management, an estimated $399M added.
- The largest Bio-Rad Laboratories Class A seller in Q2 2022 was Marshall Wace, an estimated $126M sold.
Based on aggregated 13F filings for Q2 2022.